U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.22
    +0.13 (+0.55%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.1819%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.1088%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.2696%)
     
  • BTC-USD

    19,233.08
    -11.27 (-0.06%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Recap: Xeris Pharmaceuticals Q2 Earnings

Benzinga Insights
·1 min read

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 50.78% over the past year to ($0.63), which beat the estimate of ($0.73).

Revenue of $2,027,000 up by 533.44% year over year, which beat the estimate of $1,860,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 10, 2020

View more earnings on XERS

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Price Action

Company's 52-week high was at $12.50

52-week low: $1.42

Price action over last quarter: Up 13.93%

Company Profile

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.